NORCEPT-E 1/35 28
Clinical safety rating: caution
Comprehensive clinical and safety monograph for NORCEPT-E 1/35 28 (NORCEPT-E 1/35 28).
Combination estrogen (ethinyl estradiol) and progestin (norethindrone) contraceptive: suppresses gonadotropin release, inhibits ovulation, thickens cervical mucus, and alters endometrial lining.
| Metabolism | Ethinyl estradiol: primarily metabolized by CYP3A4; norethindrone: primarily metabolized by CYP3A4 and CYP2C9. |
| Excretion | Renal (primarily as metabolites) and fecal; approximately 50-60% excreted in urine, 30-40% in feces. Ethinyl estradiol and norethindrone are extensively metabolized via hydroxylation and conjugation; glucuronide and sulfate conjugates are eliminated in urine and bile. |
| Half-life | Norethindrone: 5-14 hours; ethinyl estradiol: 13-27 hours. The terminal half-life of norethindrone is about 10 hours, allowing once-daily dosing; ethinyl estradiol's longer half-life contributes to steady-state concentrations within 3-5 days. |
| Protein binding | Norethindrone: >97% bound to albumin and SHBG; ethinyl estradiol: >97% bound to albumin. Ethinyl estradiol also binds to SHBG with lower affinity. |
| Volume of Distribution | Norethindrone: approximately 3.5 L/kg; ethinyl estradiol: approximately 2.5 L/kg. These values reflect extensive tissue distribution and binding to tissues such as breast, uterus, and adipose. |
| Bioavailability | Oral: Norethindrone ~64% (first-pass metabolism); ethinyl estradiol ~40-50% (extensive first-pass metabolism). Factors such as food and individual differences may affect bioavailability. |
| Onset of Action | Oral: 1-2 hours for hormonal effects; contraceptive efficacy requires 7 days of consistent dosing for full suppression of ovulation. Effects on cervical mucus and endometrium begin within the first few days. |
| Duration of Action | 24 hours for contraceptive effect with daily dosing. Withdrawal bleeding occurs 2-3 days after the last active pill. Hormonal effects persist for about 7 days after discontinuation before ovulation may resume. |
1 tablet orally once daily for 21 days, followed by 7 days of placebo tablets.
| Dosage form | TABLET |
| Renal impairment | No dose adjustment required for mild to moderate renal impairment. Contraindicated in acute renal disease or marked renal impairment. |
| Liver impairment | Contraindicated in severe hepatic disease or liver tumors (benign or malignant). Use with caution in mild to moderate hepatic impairment; dose adjustment generally not required but monitor for adverse effects. |
| Pediatric use | Not indicated for use before menarche. After menarche, use same adult dosing schedule. |
| Geriatric use | No specific dose adjustment; use with caution due to increased risk of thromboembolic disorders and cardiovascular events in women over 35 who smoke. |
| 1st trimester | Consult provider |
| 2nd trimester | Consult provider |
| 3rd trimester | Consult provider |
Clinical note
Comprehensive clinical and safety monograph for NORCEPT-E 1/35 28 (NORCEPT-E 1/35 28).
| Breastfeeding | Small amounts of ethinyl estradiol and norethindrone are excreted into breast milk (M/P ratio for ethinyl estradiol approximately 0.75; for norethindrone, about 0.66). Use may reduce milk production and quality, especially in early postpartum. Avoid in nursing mothers unless essential; alternative contraception recommended. |
| Teratogenic Risk | First trimester: Increased risk of neural tube defects, cardiovascular malformations, and limb reduction defects if inadvertently exposed to the progestin component (norethindrone) at high doses. Second and third trimesters: No evidence of teratogenicity from estrogen-progestin combinations; however, androgenic effects (pseudohermaphroditism in female fetuses) have been reported with high doses of progestins. Overall, combination oral contraceptives are contraindicated in pregnancy. |
■ FDA Black Box Warning
Cigarette smoking increases risk of serious cardiovascular events (thrombosis, stroke, myocardial infarction) from combination oral contraceptives, especially in women over 35 and heavy smokers (>15 cigarettes/day).
| Serious Effects |
["Thrombophlebitis or thromboembolic disorders","History of DVT/PE","Cerebrovascular or coronary artery disease","Known or suspected breast cancer","Endometrial cancer or other estrogen-dependent neoplasia","Undiagnosed abnormal genital bleeding","Cholestatic jaundice of pregnancy or jaundice with prior pill use","Hepatic adenoma or carcinoma","Known or suspected pregnancy","Hypersensitivity to any component"]
| Precautions | ["Thrombotic disorders (DVT, PE, stroke, MI)","Hepatic tumors","Hypertension","Gallbladder disease","Carbohydrate/lipid metabolism effects","Ocular lesions (retinal thrombosis)","Hereditary angioedema","Chloasma","Depression"] |
Loading safety data…
| Fetal Monitoring | Monitor blood pressure (risk of hypertension), liver function (cholestasis), and glucose tolerance (insulin resistance). Assess for thrombotic events (DVT, PE) due to estrogen component. In fetus: ultrasound if inadvertent pregnancy exposure occurs. |
| Fertility Effects | Suppresses ovulation via inhibition of gonadotropin release. Return to fertility is typically rapid (within 1-2 cycles) after discontinuation. No permanent negative effects on fertility. |